Altimmune’s (ALT) Three Liver Trials Move Forward At Once

Altimmune has begun a Phase 3 trial for pemvidutide, a dual-hormone drug targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug uniquely balances glucagon and GLP-1 receptor activation, aiming to address liver fat and fibrosis. The trial's success could validate its differentiation in a crowded market. Altimmune's valuation is highly dependent on the outcome, with a price-to-sales ratio of 72.5x.

Lululemon (LULU), Lucid (LCID), and Altimmune (ALT) hit 52-week lows due to leadership uncertainty, financial strain, and strategic concerns. LULU dropped 13% after naming a new CEO, LCID fell 9% amid funding and production cost worries, and ALT declined 16% following a stock offering. Uber owns 11.52% of LCID.

Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Altimmune Announces Second Quarter 2026 Financial Results and Business Update ​ Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.